|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Challenge of liver disease in systemic lupus erythematosus:Clues for diagnosis and hints for pathogenesis显示文摘Systemic lupus erythematosus(SLE) encompass a broad spectrum of liver diseases. We propose here to classify them as follows:(1) immunological comorbilities(overlap syndromes);(2) non-immunological comorbilities associated to SLE; and(3) a putative liver damage induced by SLE itself, referred to as 'lupus hepatitis'. In the first group, liver injury can be ascribed to overlapping hepatopathies triggered by autoimmune mechanisms other than SLE occurring with higher incidence in the context of lupus(e.g., autoimmune hepatitis, primary biliary cirrhosis). The second group includes non-autoimmune liver diseases, such as esteatosis, hepatitis C, hypercoagulation state-related liver lesions, hyperplasic parenchymal and vascular lesions, porphyria cutanea tarda, and drug-induced hepatotoxicity. Finally, the data in the literature to support the existence of a hepatic disease produced by SLE itself, or the occurrence of a SLE-associated prone condition that increases susceptibility to acquire other liver diseases, is critically discussed. The pathological mechanisms underlying each of these liver disorders are also reviewed. Despite the high heterogeneity in the literature regarding the prevalence of SLE-associated liver diseases and, in most cases, lack of histopathological evidence or clinical studies large enough to support their existence, it is becoming increasingly apparent that liver is an important target of SLE. Consequently, biochemical liver tests should be routinely carried out in SLE patients to discard liver disorders, particularly in those patients chronically exposed to potentially hepatotoxic drugs. Diagnosing liver disease in SLE patients is always challenging, and the systematization of the current information carried out in this review is expected to be of help both to attain a better understanding of pathogenesis and to build an appropriate work-up for diagnosis. | Ferno Bessone Natalia Poles Marcelo G Roma | 2014 | World Journal of Hepatology2014，6，6： | 7 |
| 2 | Dynamic localization of hepatocellular transporters in health and disease显示文摘Vesicle-based traffi cking of hepatocellular transporters involves delivery of the newly-synthesized carriers from the rough endoplasmic reticulum to either the plasma membrane domain or to an endosomal,submembrane compartment,followed by exocytic targeting to the plasma membrane. Once delivered to the plasma membrane,the transporters usually undergo recycling between the plasma membrane and the endosomal compartment,which usually serves as a reservoir of pre-existing transporters available on demand. The balance between exocytic targeting and endocytic internalization from/to this recycling compartment is therefore a chief determinant of the overall capability of the liver epithelium to secrete bile and to detoxify endo and xenobiotics. Hence,it is a highly regulated process. Impaired regulation of this balance may lead to abnormal localization of these transporters,which results in bile secretory failure due to endocytic internalization of key transporters involved in bile formation. This occurs in several experimental models of hepatocellular cholestasis,and in most human cholestatic liver diseases. This review describes the molecular bases involved in the biology of the dynamic localization of hepatocellular transporters and its regulation,with a focus on the involvement of signaling pathways in this process. Their alterations in different experimental models of cholestasis and in human cholestatic liver disease are reviewed. In addition,the causes explaining the pathological condition (e.g. disorganization of actin or actin-transporter linkers) and the mediators involved (e.g. activation of cholestatic signaling transduction pathways) are also discussed. Finally,several experimental therapeutic approaches based upon the administration of compounds known to stimulate exocytic insertion of canalicular transporters (e.g. cAMP,tauroursodeoxycholate) are described. | Marcelo G Roma Fernando A Crocenzi Aldo D Mottino | 2008 | World Journal of Gastroenterology2008，14，44： | 2 |
| 3 | CIN:multicentric study of therapeutic strategies显示文摘 | Di Roma E Parlavecchio E Vettraino G | 2001 | Minerva Ginecol2001，53，6： | 1 |
| 4 | CIN: multi-centric study of therapeutic strategies显示文摘 | Di Roma E Parlavecchio E Vettraino G | 2001 | Minerva Ginecol2001，53，6： | 1 |
| 5 | Integrin be-ta2-chain (CD18 ) over-expression on CD4+ T cells andmonocytes after ischemia/ reperfusion in patients undergo-ing primary percutaneous revascularization 显示文摘 | Sardella G Accapezzato D Di Roma A | 2003 | Int J Im-mun Pharmacol2003，17，2： | 1 |
| 6 | Brain hypoperfusion: a critical facror in vascular de- mentia 显示文摘 | Roma G C | 2004 | Neurol Res2004，26，： | 1 |
| 7 | Integrin beta2-chain (CD18) over-expression on CD4+ T cells and monocytes after ischemia/reperfusion in patients undergoing primary percutaneous revascularization显示文摘 | Sardella G Accapezzato D Di Roma A | 2004 | Int J Immunopathol Pharmacol2004，17，2： | 1 |
| 8 | CIN;muhicentric study of rapeutic strategies 显示文摘 | DI ROMA E PARLAVECCHIO E VETTRAINO G | 2001 | Minerva Ginecol2001，53，： | 1 |
| 9 | Designing multi-attribute auctions for engineering services procurement in new product development in the automotive context显示文摘 | Perrone G Roma P Nigro G L | 2010 | International Journal of Production Economies2010，124，1： | 1 |
| 10 | lntegrin beta2-chain (CDI8) over-expression on CD4+ T cells and monocytes after ischemia/reperfusion in patients undergoing primary percutaneous revascularization 显示文摘 | Sardella G Aeeapezzato D Di Roma A | 2004 | Int J Immunopathol Pharmacol2004，17，2： | 1 |
| 11 | In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissue using thin-slice echo-planar imaging显示文摘 | Manenti G Squillaci E Di Roma M | | 0，，08： | 1 |
| 12 | Designing multi-attribute auctions for engineering servicesprocurement in new product development in the automotive context 显示文摘 | Perrone G Roma P Nigro G L | 2010 | International Journalof Production Economics、2010，124，： | 1 |
| 13 | Designing multi-attribute auctions for engineering services procurement in new product de- velopment in the automotive context显示文摘 | Perrone G Roma P Nigro G L | 2010 | International Journal of Production Economics2010，124，： | 1 |
| 14 | Integrin beta2-chain (CD18) over-expression on CD4 + T cells and monocytes after ischemia/reperfusion in patients undergoing primary percutaneous revascularization 显示文摘 | Sat'della G Accapezzato D Di Roma A | 2004 | Int J Immunopathol Pharmacol2004，17，2： | 1 |
| 15 | Integrin beta2- on CD4 ~ Tcells and monocytes patients undergoing primary percutaneous revascularization 显示文摘 | Sardella G Accapezzato D Di chain ( CDIs ) over-expression afterischemia/reperfusion in Roma A | 2004 | Int J Immunopathol Pharmacol2004，17，2： | 1 |
| 16 | Silymarin as a new hepatoprotective a- gent in experimental cholestasis: new possibilities for an ancient medication 显示文摘 | Crocenzi F A Roma M G | 2006 | Curr Med Chem2006，13，9： | 1 |
| 17 | Development of broodstock diets for the European sea bass (Dicentrarchus Labrax) with special emphasis on the important of n-3 and n-6 highly unsaturated fatty acid to reproductive performance 显示文摘 | Bruce M P Oyen F Bell G Asturiano J F Farndale B Carrillo M Zanuy S Romas J Bromage N | 1999 | Aquaculture1999，177，： | 1 |
| 18 | Apoptosis and proliferation of endothelial cells in early atheroSclerotic lesions: possible role of oxidised LDL显示文摘 | Norata G D Tonti L Roma P | 2002 | Nutr Metab Cardiovasc Dis2002，12，5： | 1 |
| 19 | Italian market fish species identification and commercial frauds revealing by DNA se- quencing显示文摘 | Cutarelli A Amoroso M G De Roma A et at | 2014 | Food Control2014，37，： | 1 |
| 20 | CIN:muhicentrico study of therapeutic strategies 显示文摘 | Di Roma E Parlavecchio E Vettraino G | 2001 | Minerva Gineco12001，53，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员